Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
Summary
Fox Foundation is joining our efforts to develop a novel treatment for Parkinsons disease," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. Omeros earlier studies conducted at Emory University by Gary W. Miller, Ph.D. in a similar model showed that compounds blocking this novel target were as effective as levodopa, or L-DOPA, at doses 50- to 100-times lower than those of L-DOPA. L-DOPA has been the standard treatment for Parkinsons disease for nearly 40 years but is associated with profound side effects including dyskinesias, hallucinations, sleep disorders and cognitive impairment. Omeros plans to explore the clinical utility of one or more of the compounds currently under evaluation both singly and in conjunction with L-DOPA.Parkinsons disease, a degenerative disorder of the central nervous system, often impairs motor skills, speech and other functions. RLS is estimated to affect as many as 12 million Americans, but the incidence could be significantly higher due to under- or misdiagnosis.Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.